Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $1.8 million.

  • Enanta Pharmaceuticals' Other Accumulated Expenses fell 41.69% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 41.69%. This contributed to the annual value of $1.8 million for FY2025, which is 41.69% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $1.8 million for FY2025, which was down 41.69% from $3.1 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Other Accumulated Expenses peaked at $6.1 million during FY2023, and registered a low of $1.8 million during FY2025.
  • Its 3-year average for Other Accumulated Expenses is $3.7 million, with a median of $3.1 million in 2024.
  • In the last 5 years, Enanta Pharmaceuticals' Other Accumulated Expenses rose by 12.11% in 2021 and then slumped by 49.56% in 2024.
  • Enanta Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $6.1 million in 2021, then decreased by 8.74% to $5.5 million in 2022, then rose by 10.63% to $6.1 million in 2023, then slumped by 49.56% to $3.1 million in 2024, then plummeted by 41.69% to $1.8 million in 2025.